title: Indapamide sustained release: a review of its use in the treatment of hypertension.
abstract: A low-dose sustained-release (SR) formulation of the thiazide-type diuretic indapamide, indapamide SR (Natrilix SR), retains the antihypertensive activity of the immediate-release (IR) formulation, with a smoother pharmacokinetic profile. In well controlled 12- to 52-week clinical trials, indapamide SR 1.5 mg/day was well tolerated and reduced blood pressure as effectively as therapeutic dosages of amlodipine, candesartan, enalapril, hydrochlorothiazide or indapamide IR. Indapamide SR was also more effective than enalapril in reducing left ventricular hypertrophy (LVH), and similar reductions in renal end-organ damage, assessed by microalbuminuria, were seen with indapamide SR- and enalapril-based antihypertensive strategies. Indapamide SR provides an effective option for initial antihypertensive monotherapy and a basis for multidrug antihypertensive strategies.
authors.affiliation: Adis International Limited, Auckland, New Zealand.
authors.forename: Dean M
authors.initials: DM
authors.lastname: Robinson
authors.forename: Keri
authors.initials: K
authors.lastname: Wellington
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D007190:Indapamide / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004232:Diuretics; D007190:Indapamide